app.rxdatalab.com · Free public feature
Regulatory filings linked to clinical programs and markets. Trials, SEC filings, insider activity, and market data from primary sources.
BioHedge
Hedge fund positioning from Schedule 13D/13G filings. Each position cross-referenced with clinical trial events, regulatory filings, and insider trades. Free public view — the full platform adds company profiles, trial history, competitive landscape, and financing tracker for 500+ biotech companies.
Activity Summary
Multi-Fund Activity
Companies with two or more institutional investors filing in the same period.
Filing Volume by Week
|
Filed
|
Fund | Company | Position | Gap |
|---|---|---|---|---|
|
Oct 29, 2026
Event: 10/22/2026
Filed: Oct 29, 2026 |
AVTX
Avalo Therapeutics, Inc.
|
owns 5.2% NEW | — | |
|
AVTX
Avalo Therapeutics, Inc.
5.2%
NEW
|
||||
|
Oct 28, 2026
Event: 10/27/2026
Filed: Oct 28, 2026 |
CLYM
CLIMB BIO INC
|
owns 5.2% NEW | — | |
|
CLYM
CLIMB BIO INC
5.2%
NEW
|
||||
|
Oct 28, 2026
Event: 10/21/2026
Filed: Oct 28, 2026 |
CTNM
Contineum Therapeutics
|
owns 5.1% NEW | — | |
|
CTNM
Contineum Therapeutics
5.1%
NEW
|
||||
|
Oct 27, 2026
Event: 10/20/2026
Filed: Oct 27, 2026 |
SLGL
Sol-Gel Technologies Ltd.
|
owns 5.1% NEW | — | |
|
SLGL
Sol-Gel Technologies Ltd.
5.1%
NEW
|
||||
|
Oct 27, 2026
Event: 10/20/2026
Filed: Oct 27, 2026 |
EyePoint, Inc.
|
owns 9.6% NEW | — | |
|
EyePoint, Inc.
9.6%
NEW
|
||||
|
Oct 27, 2026
Event: 09/30/2026
Filed: Oct 27, 2026 |
IVA
Inventiva S.A.
|
owns 6.7% ▼-1.0 | 252d | |
|
IVA
Inventiva S.A.
6.7%
▼-1.0
252d
|
||||
|
Oct 26, 2026
Event: 10/19/2026
Filed: Oct 26, 2026 |
ALEC
Alector, Inc.
|
owns 5.1% NEW | 438d | |
|
ALEC
Alector, Inc.
5.1%
NEW
438d
|
||||
|
Oct 23, 2026
Event: 10/16/2026
Filed: Oct 23, 2026 |
ALEC
Alector, Inc.
|
owns 8.6% NEW | — | |
|
ALEC
Alector, Inc.
8.6%
NEW
|
||||
|
Oct 22, 2026
Event: 09/22/2026
Filed: Oct 22, 2026 |
CTNM
Contineum Therapeutics
|
owns 5.1% NEW | — | |
|
CTNM
Contineum Therapeutics
5.1%
NEW
|
||||
|
Oct 19, 2026
Event: 10/13/2026
Filed: Oct 19, 2026 |
DCTH
DELCATH SYSTEMS, INC.
|
owns 9.9% | 251d | |
|
DCTH
DELCATH SYSTEMS, INC.
9.9%
251d
|
||||
Understanding Schedule 13D and 13G Filings
Schedule 13D and 13G filings are SEC disclosures required when an investor acquires more than 5% of a company's outstanding shares.
Schedule 13D (Activist)
Filed when an investor may seek to influence management, board composition, or corporate strategy. Requires disclosure of investment purpose and plans.
Schedule 13G (Passive)
Filed by passive investors (mutual funds, index funds, institutions) with no intent to influence. Simpler filing requirements.
Gap column: Days since previous filing for the same fund+company pair.
Data source: SEC EDGAR. Filings typically available within 4 hours of submission.
This page reflects disclosed ownership changes only. Absence of activity does not imply absence of interest.
Intelligence Platform
Every event, in context.
Cross-reference each company's trial history, SEC filings, insider trades, and fund positioning in one view. Traceable to primary sources.